More than a third of Americans vaccinated; Pfizer vaccine may become first in US to get full FDA approval: Latest COVID-19 updates Elinor Aspegren, Christine Fernando and Christal Hayes, USA TODAY
Record-breaking COVID-19 wave overwhelming crematoriums, hospitals in India
Replay Video UP NEXT
Even as the pace of vaccinations falls in the U.S., the country reported passing two milestones on Friday: More than 150 million are now at least partially vaccinated, and more than a third of Americans are fully vaccinated, CDC data released Friday afternoon shows.
Data shows about 111 million Americans are fully vaccinated, about 33% of the total population in the U.S., and another 150 million people have received their fist shot of the vaccine. But the pace of vaccinations has been slowing from its peak on April 10 of 4.6 million daily shots. Public health agencies are working harder to get shots in arms, a critical effort that could help President Joe Biden s new go
.The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.
.The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.
WHO panel OKs emergency use of China s Sinopharm vaccine – The Zimbabwe Mail thezimbabwemail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thezimbabwemail.com Daily Mail and Mail on Sunday newspapers.